Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05491525 · ClinicalTrials.gov registry record · Phase 2
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC
A Phase 2 study of Neurogenic Detrusor Overactivity, sponsored by Urovant Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 6
- Study locations
NCT05491525: Recruiting Phase 2 study of Neurogenic Detrusor Overactivity, sponsored by Urovant Sciences.
NCT05491525 is a Phase 2 study of Neurogenic Detrusor Overactivity that is actively recruiting participants, run by Urovant Sciences. The registered enrollment target is 85 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05491525, a Phase 2 study of Neurogenic Detrusor Overactivity, is actively recruiting participants, sponsored by Urovant Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC
Conditions Studied
Interventions
- DRUG Vibegron
Study Locations (6)
California
- Children's Hospital of Orange County - Orange
Florida
- Nemours Childrens Health, Jacksonville - Jacksonville
Kansas
- Wichita Urology Group - Wichita
Louisiana
- Childrens Hospital New Orleans - New Orleans
New York
- Albany Medical College - Albany
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT05491525 shows while recruiting
NCT05491525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Neurogenic Detrusor Overactivity appearing as the primary indexed condition, and to 1 intervention - of which Vibegron is the first listed.
NCT05491525 lists 6 locations in 6 states (California, Florida, Kansas).
Frequently Asked Questions
What is clinical trial NCT05491525 about?
NCT05491525 is a clinical study titled "A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC". The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC
What is the current status of trial NCT05491525?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2022-10-12. Estimated completion is 2027-09.
What conditions does trial NCT05491525 study?
This clinical trial studies the following conditions: Neurogenic Detrusor Overactivity.
What interventions are being tested in trial NCT05491525?
The interventions under investigation include: Vibegron (DRUG).
Who is sponsoring clinical trial NCT05491525?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05491525 being conducted?
This trial has 6 study locations across California, Florida, Kansas, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurogenic Detrusor Overactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05491525's enrollment target sits among peer trials
85 820th of 2000 higher than 1,180 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
RECRUITING · Phase 1
-
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI